MRT Stability for Prostate Cancer

Phase-Based Progress Estimates
Victoria General Hospital, Halifax, Canada
Prostate Cancer+1 More
MRT Stability - DiagnosticTest
Any Age
Eligible conditions

Study Summary

Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour

See full description

Eligible Conditions

  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Prostate Cancer

Study Objectives

This trial is evaluating whether MRT Stability will improve 3 primary outcomes and 1 secondary outcome in patients with Prostate Cancer. Measurement will happen over the course of 8 weeks.

8 weeks
MRT Classification: Week 8
Year 2
Model optmization with novel radiomic features and clinical covariates
MRT Classification: Baseline
Baseline, 8 weeks
MRT Classification Change

Trial Safety

Safety Progress

1 of 3

Other trials for Prostate Cancer

Trial Design

1 Treatment Group

Prospective Cohort
1 of 1
Experimental Treatment

This trial requires 60 total participants across 1 different treatment group

This trial involves a single treatment. MRT Stability is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Prospective CohortSixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at study completion, 2 years.
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly at study completion, 2 years. for reporting.

Who is running the study

Principal Investigator
M. K.
Mike Kucharczyk, Radiation Oncologist
Nova Scotia Health Authority

Closest Location

Victoria General Hospital - Halifax, Canada

Eligibility Criteria

This trial is for male patients of any age. There are 9 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Being performed on 3T MRI at the Halifax Infirmary Building
Taken place within 5 weeks of study enrolment
Having a detectable nodule which anatomically localizes to prostate cancer (PCa) identified in diagnostic biopsy specimen
Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial images of the prostate
Taken place within 2 months of the participant's MRI-P 1
Taken place within 3 months of participant's study enrolment
Reports diagnosis of PCa
Reports a systematic assessment of the biopsy, assessing at least 12 cores
Reports at least on core involved with PCa and this core must anatomically localise to a nodule seen on MRI-P 1

Patient Q&A Section

Can prostate cancer be cured?

"In [prostate cancer](, definitive treatment and PSA surveillance alone were not associated with clinically significant change in time to prostatectomy, as well as the progression-free probability and overall survival. In a recent study, findings suggest that radical prostatectomy in lieu of watchful waiting may offer patients more favorable outcomes without delaying time to salvage therapy." - Anonymous Online Contributor

Unverified Answer

What are the signs of prostate cancer?

"Signs of prostate cancer can include unexplained fever, swollen or hard lymph nodes, persistent pain with urination or tiredness and difficulty starting to ejaculate. Other signs of prostate cancer include loss of semen and trouble starting to have sex.\n" - Anonymous Online Contributor

Unverified Answer

What is prostate cancer?

"Prostate cancer is a cancer that forms in the prostate and typically appears in men over the age of 50. It is often identified by frequent, painful or bloody urination or painful ejaculation. Prostate cancer affects about 1 in 3 men over the age of 50. It is one of the most significant causes of death from cancer in the developed world. Prostate cancer is one of the few cancers with a mortality rate more than fivefold higher among black than white men. The average age of diagnosis in the U.S. is 80, and in most developed countries it is much later. Prostate cancer is common, with the highest rates in the developed world, except for Western Australia, where prostate cancer occurs far more often than expected." - Anonymous Online Contributor

Unverified Answer

What are common treatments for prostate cancer?

"Common treatments for prostate cancer include watchful waiting, minimally invasive forms of treatment, hormonal agents (androgen deprivation therapy) and radiation therapy. Immunotherapy has also been studied.\n" - Anonymous Online Contributor

Unverified Answer

What causes prostate cancer?

"The prostate is not a cancer-prone organ. Instead, prostate cancer mainly arises because the prostate retains cells after a prostatectomy. Therefore, it is the removal or destruction of the prostate cells that leads to prostate cancer - and not an environmental risk factor." - Anonymous Online Contributor

Unverified Answer

How many people get prostate cancer a year in the United States?

"The data are interpreted to indicate that the incidence of prostate cancer in the general US population may be about equal to the incidence in Sweden. If an average of 0.9 cases for every 100,000 men was assumed, the overall incidence in the United States would be about 3.5 cases per 100,000 men." - Anonymous Online Contributor

Unverified Answer

What does mrt stability usually treat?

"Findings from a recent study found that, in the general community, the only factor shown to be highly predictive of mrt metastatic relapse was stability on first treatment, whereas no other variable demonstrated the best outcome. Findings from a recent study suggest that stability of metastatic prostate cancer lesions on treatment is a promising potential outcome variable for metastatic prostate cancer treatment, although this must be confirmed in future, randomized studies." - Anonymous Online Contributor

Unverified Answer

Is mrt stability safe for people?

"Results from a recent paper demonstrates for the first time that the stability of mrt is not affected by people with malignant mesothelioma. We therefore recommend that it can be safely administered to people with malignant mesothelioma." - Anonymous Online Contributor

Unverified Answer

Have there been other clinical trials involving mrt stability?

"Previous mrt trials have generally observed relatively low efficacy compared to other cancer therapies. Despite its relatively limited efficacy, radiotherapy is still an effective treatment for selected, metastatic and locally advanced prostate cancer indications, where it is most often initiated as the sole treatment." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in mrt stability for therapeutic use?

"While MR is still the mainstay for most people, with the improvements noted in equipment and scan protocols. This is a major step forward, both technical and from a therapeutic perspective." - Anonymous Online Contributor

Unverified Answer

How serious can prostate cancer be?

"Most often prostate cancer is mild or moderately serious. To facilitate the discussion, the seriousness of prostate cancer was divided into mild, moderate, and severe with respect to the risk of dying within the first year after diagnosis or death at all. While there are patients with severe prostate cancer in whom cure by surgery is unlikely, the vast majority of patients do not die within a year of diagnosis and/or surgery." - Anonymous Online Contributor

Unverified Answer

Has mrt stability proven to be more effective than a placebo?

"Results from a recent clinical trial demonstrate that patients receiving the MRT were as effective as placebo users with respect to symptom control and quality of life, while MRT showed no adverse effects in terms of QOL and symptom control. Although the results indicate MRT to be effective, several patient specific factors including age, education, and employment status affect outcomes. Further study is needed to validate the efficacy and safety of MRT." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.